Navigation Links
Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study
Date:3/4/2008

The Massachusetts General Hospital (MGH) has received a five-year, $20.5 million grant from the Bill & Melinda Gates Foundation to expand an international program investigating the biological factors underlying immune system control of HIV, the virus that causes AIDS. The grant provides support to the International HIV Controllers Study, which currently involves researchers from more than a dozen countries and has the overall goal of discovering information that can guide design of a vaccine to limit viral replication in HIV-infected individuals. A primary focus will be understanding genetic and immunological factors that have allowed a few individuals to control HIV naturally without the need for medications, some for more than 25 years.

The grant is part of the Collaboration for AIDS Vaccine Discovery, an international network of research consortia funded by the Gates Foundation to address priorities in the Global HIV Vaccine Enterprise scientific plan.

We believe that it is critical to understand how these individuals who are maintaining viral levels so low that transmission and disease progression should decrease markedly are keeping the virus in check and preventing it from causing disease, says Bruce Walker, MD, director of the Partners AIDS Research Center at MGH and principal investigator of the Gates Foundation grant. By recruiting enough of these individuals, we hope to identify the genetic basis for this viral control, using novel methods developed for the Human Genome Project. We believe this approach is all the more important given recent setbacks in HIV vaccine trials.

For more than 15 years it has been apparent that a small minority of HIV-positive people remained healthy despite many years of infection. As techniques for measuring viral levels in the bloodstream became more sensitive, it was possible to identify this group of viremic controllers, who can maintain viral loads below 2,000 copies/ml, and an even s
'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. AIDS Action Asks Mass. Public Health Council to Forge a State AIDS Plan to Help Stop HIV/AIDS Here
2. Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed
3. Mass. Judge Denies Request by Breastfeeding Mother for More Break Time on Medical Licensing Exam
4. Accident Fund Names General Agency Company its 2007 Agency of the Year
5. TransUnion Addresses Ohio Attorney Generals Concerns Surrounding Non-Profit Tax-Exempt Status
6. Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Caremark
7. AHIP Statement on New York Attorney Generals Announcement
8. SearchMedicas Second Quarterly Top Clinical Search Terms Report Reveals Top 25 Oncology, General Medicine and Psychiatry Search Terms Among Medical Professionals
9. General Atlantic and Hellman & Friedman Purchase HLTH Corporations Remaining Interest in Emdeon
10. HLTH Corporation Sells its Minority Interest in Emdeon Business Services to General Atlantic and Hellman & Friedman for $575 Million
11. Former Navy Surgeon General Is Among Three New Accomplished TriWest Advisory Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2009)... can help prevent pain and injury, doctors say ,...hile baby boomers are not as young as they used to...rtain precautions are in order to stay injury-free...steps to protect themselves from injuries when exe...can Academy of Orthopaedic Surgeons, said in a new...
(Date:7/3/2009)... Reward and recognise service excellence during Na... London (PRWeb UK) July 3, 20...K are being urged to celebrate the importance of e...al Customer Service Week - 5-11 October., , ,Emplo...the corner shop and local authority see the week, ...
(Date:7/3/2009)...divorce or death in middle age may triple the risk...thDay News) -- Middle-aged adults who live alone a...r,s disease later in life compared to those who ar...three times higher among those who are divorced or...Finnish researchers. , The study included 2,000...
(Date:7/3/2009).../PRNewswire-Asia/ -- Sundia MediTech, a leading,i...urcing company in Shanghai,China announced today...,President of Chemistry Services. , Prior ...iosciences, a drug,discovery and development comp...scientist to Senior Director of Medicinal Chemistr...
Breaking Medicine News(10 mins):Health News:Exercise Tips to Keep Boomers on Their Feet 2Health News:Businesses Urged to Sign Up and Celebrate Customer Service 2Health News:Living Alone Increases Odds of Developing Dementia 2Health News:Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry 2
...e surgical technique involving Botox brings relief...go, Sharon Schafer Bennett suffered from migraines...kept her from seeking a job and interfered with pa...n's daily activities. Now, thanks to an innovativ...
...sophila fruit fly may pave the way to new methods ...ase//, the leading cause of death in industrialize...The study reports that mutations in a molecular ch...anes caused arrhythmias similar to those that are ...
...s are full of pleasant surprises. They don't scrap...isrupted energy flows and prescribe homeopathic re... more traditional-minded colleagues sceptical. Som...ing they all agree on. "We drill just like ordina...
...patients have cholesterol higher than national gui...nted the stroke from happening//, according to a s...ntific journal of the American Academy of Neurolog...lized for stroke or transient ischemic attack (TIA...
Other Medicine News:Health News:A Combination of Botox and Surgery Cures Migraines 2Health News:A Combination of Botox and Surgery Cures Migraines 3Health News:Fruit Flies May Pave Way to New Treatments for Age-related Heart Disease 2Health News:Fruit Flies May Pave Way to New Treatments for Age-related Heart Disease 3Health News:Homeopathy and Hypnosis Come to Dentistry 2Health News:Cholesterol in Stroke Patients Exceeds National Guidelines 2
(Date:6/28/2009)...Newswire-FirstCall/ -- Sangamo BioSciences, Inc. (...ch milestone has been achieved in its Research and...owned member of the Roche Group, for the generatio...rmaceutical protein production purposes using Sang...nuclease (ZFN) technology. Genentech scientists de...
(Date:6/26/2009)...RNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT...f data associated with a retrospective follow-up o...ta clearly show that no definitive conclusions can... between Lantus(R) (insulin glargine [rDNA] inject...e authors of the study point out. , , Clinical ...
(Date:6/25/2009)...xperts Slated to Attend First National Symposium -...e first national symposium designed to explore the... week in New York City when thirteen top experts g...respective fields. The SUNY Youth Sports Institut...th impacts that the $5 billion-a-year energy drink...
(Date:6/25/2009)...a Highlighted at the College on Problems of Drug D... 25 King Pharmaceuticals, Inc. (NY...senting safety and efficacy data for ACUROX(R) a... formulations that are in development, at the 71st... Dependence. King is also developing other pain m...
Breaking Medicine Technology:Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3Sanofi-aventis Stands Behind the Safety of Lantus(R) 2Sanofi-aventis Stands Behind the Safety of Lantus(R) 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 2SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 2King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 3King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 5King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 6Bad sign for global warming 3A Thawing permafrost holds vast carbon pool 4689 1Bad sign for global warming 3A Thawing permafrost holds vast carbon pool 4689 2Bad sign for global warming 3A Thawing permafrost holds vast carbon pool 4689 3NYU American Museum of Natural History receive 241 6 million NSF grant 4686 1NYU American Museum of Natural History receive 241 6 million NSF grant 4686 2Concentric Named Professional Agency of Record for Discovery Labs SURFAXIN 28R 29 7451 1Concentric Named Professional Agency of Record for Discovery Labs SURFAXIN 28R 29 7451 2Unexplored Arctic region to be mapped 4685 1
...- A comparison of,the long-term economic outcomes ...ith symptom management versus symptom,management a...,injection) was the most cost-effective treatment ...s (RRMS). The study provides,the first pharmacoeco...iple sclerosis (MS) therapies that includes long-t...
...irstCall/ --,Nuvelo, Inc. today announced the publ..., a secreted protein currently in preclinical,deve...tent,stimulator of gastrointestinal (GI) epithelia...ents with inflammatory bowel,conditions, including..., entitled "R-Spondin1, A Novel Intestinotrophic M...
Other Medicine Technology:First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 2First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 3First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 4First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 5First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 6Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 2Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 3Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 4
Cleveland Bone Cutter #5, 17cm, 6-3/4"
Palm Style Impactor Bone Awl with Ortho-Grip® silicone rubber handles and,stainless steel impactor caps.
CapSureSP Novus 5594 is a J-shaped, endocardial, tined pacing lead. provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but wi
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications.
Medicine Products: